Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Patients Steered to Fewer Pharmacies May Fill More Prescriptions

Lisa Rapaport  |  September 9, 2015

With diabetes drugs, the timeliness of refills increased from 76% to 77% among people who switched to narrow networks, while staying around 80% for individuals who didn’t switch.

People who transitioned to narrow networks got timely refills of antidepressants 70% of the time in 2012 and 72% of the time in 2013, while timely refills increased from about 73% to 74% among individuals who didn’t switch.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

One shortcoming of the study is that people in the plans that didn’t switch to narrow networks filled prescriptions more regularly at the start of the study, leaving less room for improvement, the authors acknowledge Sept. 8 in JAMA Internal Medicine.

They also note that they didn’t explore clinical differences among patients that might help explain the changes in rates of adherence.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

It’s possible that the narrow network plans available through CVS may not get the same results as drug benefits available elsewhere, Jack Hoadley, of the Health Policy Institute at Georgetown University in Washington, DC, noted in an accompanying editorial.

“The small gains found in adherence may be associated with more affordable co-payments, but we don’t know from the study what difference there was in co-payments,” Hoadley said by email.

“Many factors are associated with whether people fill prescriptions and take their medications, including the presence of side effects or how many drugs they are prescribed in total,” he added.

Page: 1 2 | Single Page
Share: 

Filed under:Drug Updates Tagged with:adherenceHealth InsuranceMedicationpharmacyprescription

Related Articles

    CVS Health to Acquire Aetna for $69 billion

    December 4, 2017

    (Reuters)—U.S. drugstore chain operator CVS Health Corp said on Sunday it had agreed to acquire U.S. health insurer Aetna Inc. for $69 billion, seeking to tackle soaring healthcare spending through lower-cost medical services in pharmacies. This year’s largest corporate acquisition will combine one of the nation’s largest pharmacy benefits managers (PBMs) and pharmacy operators with…

    Study Says 1 Biosimilar Switch Is OK; Jury Still Out on Multiple Switches

    August 17, 2018

    AMSTERDAM—As more biosimilar drugs for rheumatic diseases make their way to market, evidence is growing that switching from the originator drug to a biosimilar tends to be effective, while the questions of switching back and forth, and switching multiple times using several different biosimilars, remain to be answered, an expert on the topic said at…

    2014 ACR/ARHP Annual Meeting: Rheumatology Drug Updates, Safety News

    January 1, 2015

    Plus, hydrocodone combination products and brodalumab

    U.S. Drug Benefit Managers Clamp Down on Specialty Pharmacies

    November 17, 2015

    NEW YORK/LOS ANGELES (Reuters)—In recent days, the largest U.S. managers of private prescription drug benefits have cut off at least eight pharmacies that work closely with drugmakers, intensifying scrutiny of a system that helps inflate drug prices, officials at the benefit managers told Reuters. The terminations come from payers who together manage drug benefits for…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences